OB/ PHARM | Terbutaline
STAT Stitch Deep Dive Podcast Beyond The Bedside · Regular Guy
Audio is streamed directly from the publisher (content.rss.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Overview and Mechanism of Action Terbutaline sulfate is a short-acting selective beta-2 agonist (SABA) utilized primarily for the treatment and prevention of bronchospasms associated with asthma and COPD. It functions by stimulating beta-2 adrenergic receptors, which are densely located on bronchiolar smooth muscle. This stimulation activates the enzyme adenyl cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP). The resulting elevation in cAMP causes vasodilation and significant relaxation of bronchial smooth muscle, thereby increasing bronchial airflow.
The Boxed Warning on Tocolysis The most critical clinical safety information regarding terbutaline involves its off-label use for managing premature labor, or tocolysis. Because beta-2 stimulation induces uterine relaxation, it has historically been used to suppress contractions; however, this practice carries a severe Boxed Warning. Oral terbutaline is strictly contraindicated for the prevention or treatment of preterm labor due to a complete lack of demonstrated efficacy, severe maternal cardiovascular safety concerns, and the risk of neonatal hypoglycemia.
Furthermore, injectable terbutaline must never be utilized for prolonged tocolysis, defined as administration beyond 48 to 72 hours. Prolonged use has resulted in 16 maternal deaths and 12 serious maternal cardiovascular events reported to the FDA during post-marketing surveillance. Severe maternal adverse reactions include pulmonary edema, myocardial ischemia, cardiac arrhythmias, and hypokalemia. Acute, short-term use of injectable terbutaline is restricted to briefly prolonging pregnancy for 2 to 7 days, allowing just enough time for hospital transfer and the administration of antenatal corticosteroids for fetal lung maturation.
Administration and Pharmacokinetics Terbutaline can be administered orally, subcutaneously, intravenously, or via inhalation. Oral tablets may be crushed, though administering them with food reduces bioavailability by approximately one-third. Subcutaneous injections should be administered in the lateral deltoid area. While the drug can be diluted for intravenous use, continuous IV infusion is notably not FDA-approved.
The onset of therapeutic action depends heavily on the route: 5 to 30 minutes for inhalation, 30 to 60 minutes for subcutaneous injection, and 1 to 2 hours for oral doses. Bronchodilation typically lasts between 3 to 8 hours. Crucially, continuous use of beta-2 agonists over a 12-month period can dangerously accelerate the decline of lung function in asthmatic patients. Strict dose adjustments are required for renal impairment: patients with a creatinine clearance of 10–50 ml/min should receive exactly 50% of the usual systemic dose, and the drug must be completely avoided if clearance drops below 10 ml/min.
Adverse Reactions and Lactation Because beta-receptors are also present in the heart, terbutaline is inherently cardiostimulatory. The most common mild adverse reaction is a tremor, which affects between 8% and 38% of patients. Other frequent side effects include drowsiness, headaches, palpitations, and sinus tachycardia. Severe but less common reactions include seizures, pulmonary edema, and the exacerbation of arrhythmias, alongside metabolic shifts such as hypokalemia and hyperglycemia.
For lactating mothers, terbutaline is excreted in breast milk in minimal amounts. While the American Academy of Pediatrics considers it usually compatible with breastfeeding, inhaled beta-agonists (like albuterol) are heavily preferred over systemic terbutaline.